Altered Genome‑wide Hydroxymethylation Analysis for Neoadjuvant Chemoradiotherapy Followed by Surgery in Esophageal Cancer

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2022 Dec 23

PMID 36561617

Authors

Xianjing Zhang

Mingzhu Lu

Jing Zhu

Changsong Zhang

Meihua Wang

Affiliations

Soon will be listed here.

Abstract

Esophageal cancer has high incidence rate in China. Neoadjuvant chemoradiotherapy (nCRT) has become the standard treatment for esophageal squamous cell carcinoma (ESCC). However, there are few reliable epigenetic parameters for patients with ESCC undergoing neoadjuvant therapy. Genomic extract from tumor tissue was amplified and sequenced using the Illumina HiSeq4000 to quantify genes associated methylation or hydromethylation in 12 patients with ESCC undergoing nCRT. The genome-wide hydroxymethylation were analyzed by methylated and hydroxymethylated DNA immunoprecipitation sequencing by MACS2 software and UCSC RefSeq database. Abnormal DNA methylation was statistically different between nCRT-well (showed a pathological complete response to nCRT) and nCRT-poor (showed incomplete pathological response to nCRT) patients. Levels of ten-eleven translocation 1, 2 and 3 mRNA and protein were higher in tumor tissue in nCRT-well group patients than in nCRT-poor group patients. Illumina HiSeq 4000 sequencing identified 2925 hypo-differentially hydroxymethylated region (DhMRs) and 292 hyper-DhMRs in promoter between nCRT-well and nCRT-poor patients. Biological processes associated with hyper-DhMRs included 'snRNA processing', 'hormone-mediated signaling pathway' and 'cellular response'. Metabolic processes were associated with hypo-DhMRs. These data may explain the functional response to nCRT in patients with abnormal promoter of methylation gene-associated mRNA expression. The present results implied that hyper-DhMRs and hypo-DhMRs affect molecular pathways, such as hippo and Notch signaling pathways, highlighting epigenetic modifications associated with clinical response to nCRT in patients with esophageal cancer.

Citing Articles

PIWI-interacting RNA-17458 is oncogenic and a potential therapeutic target in cervical cancer.

Liu L, Li L, Zu W, Jing J, Liu G, Sun T J Cancer. 2023; 14(9):1648-1659.

PMID: 37325054 PMC: 10266240. DOI: 10.7150/jca.83446.

References

Shekhawat J, Gauba K, Gupta S, Choudhury B, Purohit P, Sharma P . Ten-eleven translocase: key regulator of the methylation landscape in cancer. J Cancer Res Clin Oncol. 2021; 147(7):1869-1879. DOI: 10.1007/s00432-021-03641-3. View

Yang P, Zhou X, Yang X, Wang Y, Sun T, Feng S . Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study. World J Surg Oncol. 2021; 19(1):333. PMC: 8609728. DOI: 10.1186/s12957-021-02446-5. View

. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017; 541(7636):169-175. PMC: 5651175. DOI: 10.1038/nature20805. View

Liu J, Li J, Lin W, Shao D, Depypere L, Zhang Z . Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study. Int J Cancer. 2022; 151(1):128-137. DOI: 10.1002/ijc.33976. View

Pfeifer G, Xiong W, Hahn M, Jin S . The role of 5-hydroxymethylcytosine in human cancer. Cell Tissue Res. 2014; 356(3):631-41. PMC: 4090033. DOI: 10.1007/s00441-014-1896-7. View

Niwa Y, Yamada S, Sonohara F, Kurimoto K, Hayashi M, Tashiro M . Identification of a serum-based miRNA signature for response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy. J Transl Med. 2019; 17(1):1. PMC: 6317218. DOI: 10.1186/s12967-018-1762-6. View

Tian X, Sun B, Chen C, Gao C, Zhang J, Lu X . Circulating tumor DNA 5-hydroxymethylcytosine as a novel diagnostic biomarker for esophageal cancer. Cell Res. 2018; 28(5):597-600. PMC: 5951904. DOI: 10.1038/s41422-018-0014-x. View

de Klerk L, Goedegebuure R, van Grieken N, van Sandick J, Cats A, Stiekema J . Molecular profiles of response to neoadjuvant chemoradiotherapy in oesophageal cancers to develop personalized treatment strategies. Mol Oncol. 2021; 15(4):901-914. PMC: 8024738. DOI: 10.1002/1878-0261.12907. View

Dagogo-Jack I, Shaw A . Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2017; 15(2):81-94. DOI: 10.1038/nrclinonc.2017.166. View

10.

Shang X, Zhang W, Zhao G, Liang F, Zhang C, Yue J . Pembrolizumab Combined With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Oesophageal Squamous Cell Carcinoma: Protocol for a Multicentre, Prospective, Randomized-Controlled, Phase III.... Front Oncol. 2022; 12:831345. PMC: 9008846. DOI: 10.3389/fonc.2022.831345. View

11.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

12.

Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z . Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial. JAMA Surg. 2021; 156(8):721-729. PMC: 8223138. DOI: 10.1001/jamasurg.2021.2373. View

13.

Lin L, Cheng X, Yin D . Aberrant DNA Methylation in Esophageal Squamous Cell Carcinoma: Biological and Clinical Implications. Front Oncol. 2020; 10:549850. PMC: 7645039. DOI: 10.3389/fonc.2020.549850. View

14.

Mori T, Kumagai K, Nasu K, Yoshizawa T, Kuwano K, Hamada Y . Clonal Expansion of Tumor-Infiltrating T Cells and Analysis of the Tumor Microenvironment within Esophageal Squamous Cell Carcinoma Relapsed after Definitive Chemoradiation Therapy. Int J Mol Sci. 2021; 22(3). PMC: 7865796. DOI: 10.3390/ijms22031098. View

15.

Slotta-Huspenina J, Drecoll E, Feith M, Habermehl D, Combs S, Weichert W . MicroRNA expression profiling for the prediction of resistance to neoadjuvant radiochemotherapy in squamous cell carcinoma of the esophagus. J Transl Med. 2018; 16(1):109. PMC: 5918871. DOI: 10.1186/s12967-018-1492-9. View

16.

Qu X, Davison J, Du L, Storer B, Stirewalt D, Heimfeld S . Identification of differentially methylated markers among cytogenetic risk groups of acute myeloid leukemia. Epigenetics. 2015; 10(6):526-35. PMC: 4623036. DOI: 10.1080/15592294.2015.1048060. View

17.

Xing J, Zhai R, Wang C, Liu H, Zeng J, Zhou D . DiseaseMeth version 3.0: a major expansion and update of the human disease methylation database. Nucleic Acids Res. 2021; 50(D1):D1208-D1215. PMC: 8728278. DOI: 10.1093/nar/gkab1088. View

18.

Jin N, George T, Otterson G, Verschraegen C, Wen H, Carbone D . Advances in epigenetic therapeutics with focus on solid tumors. Clin Epigenetics. 2021; 13(1):83. PMC: 8056722. DOI: 10.1186/s13148-021-01069-7. View

19.

Chen X, Cai S, Li B, Zhang X, Li W, Linag H . Identification of key genes and pathways for esophageal squamous cell carcinoma by bioinformatics analysis. Exp Ther Med. 2018; 16(2):1121-1130. PMC: 6090437. DOI: 10.3892/etm.2018.6316. View

20.

Zhou M, Hou P, Yan C, Chen L, Li K, Wang Y . Cell-free DNA 5-hydroxymethylcytosine profiles of long non-coding RNA genes enable early detection and progression monitoring of human cancers. Clin Epigenetics. 2021; 13(1):197. PMC: 8543867. DOI: 10.1186/s13148-021-01183-6. View